Medicine and Dentistry
Breast Cancer
100%
Lumpectomy
86%
Neoplasm
66%
Intraoperative Radiation Therapy
64%
Surgery
52%
Breast Cancer-Related Lymphedema
48%
Intraductal Carcinoma
40%
Radiation Therapy
38%
Biopsy
36%
Mastectomy
36%
Quadrantectomy
35%
Malignant Neoplasm
32%
Wilms' Tumor
32%
Disease
29%
Surgeon
29%
Minimal Residual Disease
24%
Recurrent Disease
20%
Multivariate Analysis
20%
Lymph Node
20%
Cancer Diagnosis
20%
Reoperation
18%
Systematic Review
18%
Vasopressin
16%
Overall Survival
16%
Artery
16%
Ganglioneuroblastoma
16%
Acinar Cell
16%
Retrospective Study
16%
Underserved Population
16%
Cancer Therapy
16%
Clear Cell Renal Cell Carcinoma
16%
Salivary Gland
16%
Pediatrics
16%
Mucoepidermoid Carcinoma
16%
Cancer Risk
16%
Atypical Hyperplasia
16%
Cystadenoma
16%
Collaborative Learning
16%
in Vivo Dosimetry
16%
Hemorrhagic Cystitis
16%
Shared Decision Making
16%
Anaplastic Carcinoma
16%
Lobular Carcinoma in Situ
16%
Patient with Neuroblastoma
16%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
16%
Coronavirinae
16%
Pandemic
16%
Recurrence Risk
14%
Odds Ratio
13%
Celiac Artery
12%
Keyphrases
Breast Cancer-related Lymphedema
32%
Lumpectomy
32%
Postoperative Morbidity
16%
Positive Margins
16%
Collaboration Protocol
16%
Mucoepidermoid
16%
Visceral Artery
16%
Nipple
16%
Local Control
16%
Breast Surgeon
16%
Chest Wall Involvement
16%
Oncoplastic Breast Surgery
16%
Bridge Measurements
16%
High-risk Neuroblastoma
16%
Reoperation
16%
Ethnically Diverse Populations
16%
Breast Cancer Prevention
16%
Skin Bridge
16%
Intraoperative Radiation Therapy
16%
Axillary Reverse Mapping
16%
Re-resection
16%
Underserved
16%
Breast
16%
Targeted Intraoperative Radiotherapy
16%
Synchronous Bilateral Breast Cancer
16%
Re-excision
16%
Breast Cancer Diagnosis
16%
American Society
16%
Clinical Utility
16%
Cavity Margin
16%
Postoperative Mortality
16%
HER2-positive Breast Cancer
16%
Neoadjuvant
16%
T-DM1
16%
Bridging Strategy
16%
Coronavirus disease-19 Pandemic
16%
Re-excision Rate
13%
Bilateral Breast Cancer
12%
Ethnic Minorities
10%
Reoperation Rate
9%
Laparoscopic Biopsy
8%
Atypical Breast Lesions
8%
Breast Cancer Patients
6%
Local Recurrence Rate
6%
MYCN Amplification
6%
Locally Recurrent
6%
High-risk Population
6%
Axillary Lymph Node Dissection
6%
Optically Stimulated Luminescence Dosimeter
6%
Mortality Rate
6%
